Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Status: Enrolling
Updated:  6/25/2014
University of Iowa
mi
from
Iowa City, IA
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Status: Enrolling
Updated: 6/25/2014
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Status: Enrolling
Updated:  6/25/2014
Mid Carolina Cardiology
mi
from
Charlotte, NC
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Status: Enrolling
Updated: 6/25/2014
Mid Carolina Cardiology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Status: Enrolling
Updated:  6/25/2014
Eastside Cardiology
mi
from
Kirkland, WA
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial
Status: Enrolling
Updated: 6/25/2014
Eastside Cardiology
mi
from
Kirkland, WA
Click here to add this to my saved trials
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Status: Enrolling
Updated:  7/6/2014
Mayo Clinic Chest Pain Unit, Emergency Department
mi
from
Rochester, MN
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Status: Enrolling
Updated: 7/6/2014
Mayo Clinic Chest Pain Unit, Emergency Department
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy of Buffered Lidocaine in Patients With Facial Swelling
Anesthetic Efficacy of 4% Buffered Lidocaine in Emergency Patients With Facial Swelling.
Status: Enrolling
Updated:  7/7/2014
The Ohio State University, College of Dentistry
mi
from
Columbus, OH
Efficacy of Buffered Lidocaine in Patients With Facial Swelling
Anesthetic Efficacy of 4% Buffered Lidocaine in Emergency Patients With Facial Swelling.
Status: Enrolling
Updated: 7/7/2014
The Ohio State University, College of Dentistry
mi
from
Columbus, OH
Click here to add this to my saved trials
Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation
Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation on the Results of Stent Deployment
Status: Enrolling
Updated:  7/11/2014
John L. McClellan Memorial Veterans Hospital
mi
from
Little Rock, AR
Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation
Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation on the Results of Stent Deployment
Status: Enrolling
Updated: 7/11/2014
John L. McClellan Memorial Veterans Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Status: Enrolling
Updated:  7/15/2014
Desert Heart
mi
from
Palm Springs, CA
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Status: Enrolling
Updated: 7/15/2014
Desert Heart
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Status: Enrolling
Updated:  7/15/2014
North Coast Cardiology
mi
from
Encinitas, CA
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation
Status: Enrolling
Updated: 7/15/2014
North Coast Cardiology
mi
from
Encinitas, CA
Click here to add this to my saved trials
HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia
HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia
Status: Enrolling
Updated:  7/23/2014
The Mayo Clinic
mi
from
Rochester, MN
HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia
HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia
Status: Enrolling
Updated: 7/23/2014
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.
Mapping of the Coronary Venous System in Patients With Heart Failure Presenting for CRT-D (Cardiac Resynchronization Therapy) Implantation. Correlating QLV Interval to Fluoroscopic LV (Left Ventricular) Lead Position.
Status: Enrolling
Updated:  7/24/2014
The University of California, San Diego
mi
from
La Jolla, CA
Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.
Mapping of the Coronary Venous System in Patients With Heart Failure Presenting for CRT-D (Cardiac Resynchronization Therapy) Implantation. Correlating QLV Interval to Fluoroscopic LV (Left Ventricular) Lead Position.
Status: Enrolling
Updated: 7/24/2014
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status: Enrolling
Updated:  7/24/2014
University of Michigan Congenital Heart Center
mi
from
Ann Arbor, MI
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status: Enrolling
Updated: 7/24/2014
University of Michigan Congenital Heart Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status: Enrolling
Updated:  7/24/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status: Enrolling
Updated: 7/24/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status: Enrolling
Updated:  7/24/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation
Status: Enrolling
Updated: 7/24/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
Status: Enrolling
Updated:  7/28/2014
Clinical Research Facility
mi
from
Arcadia, CA
A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
Status: Enrolling
Updated: 7/28/2014
Clinical Research Facility
mi
from
Arcadia, CA
Click here to add this to my saved trials
A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
Status: Enrolling
Updated:  7/28/2014
HyperBarxs at Northside Forsyth
mi
from
Cumming, GA
A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers
Status: Enrolling
Updated: 7/28/2014
HyperBarxs at Northside Forsyth
mi
from
Cumming, GA
Click here to add this to my saved trials
Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)
Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in Heart Failure Patients (CONFIRM-HF)
Status: Enrolling
Updated:  7/28/2014
Thomas Jefferson University
mi
from
Philadelphia, PA
Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)
Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in Heart Failure Patients (CONFIRM-HF)
Status: Enrolling
Updated: 7/28/2014
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Venous Thromboembolic Prophylaxis After Major Trauma: A Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
Status: Enrolling
Updated:  7/30/2014
Scripps Mercy Hospital
mi
from
San Diego, CA
Venous Thromboembolic Prophylaxis After Major Trauma: A Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
Status: Enrolling
Updated: 7/30/2014
Scripps Mercy Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Columbus, OH
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome
Study of a Positive Psychology Program to Improve Healthy Behaviors After an Acute Coronary Syndrome: Proof of Concept Study
Status: Enrolling
Updated:  8/7/2014
Massachusetts General Hospital
mi
from
Boston, MA
Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome
Study of a Positive Psychology Program to Improve Healthy Behaviors After an Acute Coronary Syndrome: Proof of Concept Study
Status: Enrolling
Updated: 8/7/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cardiometabolic Risk in Cardiac Rehab
Cardiometabolic Risk in the Setting of Cardiac Rehabilitation
Status: Enrolling
Updated:  8/18/2014
Holy Spirit Hospital and Health Center
mi
from
Camp Hill, PA
Cardiometabolic Risk in Cardiac Rehab
Cardiometabolic Risk in the Setting of Cardiac Rehabilitation
Status: Enrolling
Updated: 8/18/2014
Holy Spirit Hospital and Health Center
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Cardiometabolic Risk in Cardiac Rehab
Cardiometabolic Risk in the Setting of Cardiac Rehabilitation
Status: Enrolling
Updated:  8/18/2014
Ephrata Community Hospital
mi
from
Ephrata, PA
Cardiometabolic Risk in Cardiac Rehab
Cardiometabolic Risk in the Setting of Cardiac Rehabilitation
Status: Enrolling
Updated: 8/18/2014
Ephrata Community Hospital
mi
from
Ephrata, PA
Click here to add this to my saved trials
Cardiometabolic Risk in Cardiac Rehab
Cardiometabolic Risk in the Setting of Cardiac Rehabilitation
Status: Enrolling
Updated:  8/18/2014
Lancaster Heart & Vascular Institution, Cardiac Rehab
mi
from
Lancaster, PA
Cardiometabolic Risk in Cardiac Rehab
Cardiometabolic Risk in the Setting of Cardiac Rehabilitation
Status: Enrolling
Updated: 8/18/2014
Lancaster Heart & Vascular Institution, Cardiac Rehab
mi
from
Lancaster, PA
Click here to add this to my saved trials
Prevalence of MTHFR Polymorphisms in Venous Disease
Prevalence of MTHFR Polymorphisms in Venous Disease With or Without Concomitant Thrombosis
Status: Enrolling
Updated:  8/18/2014
The Elite Laser Vein Center
mi
from
Los Angeles, CA
Prevalence of MTHFR Polymorphisms in Venous Disease
Prevalence of MTHFR Polymorphisms in Venous Disease With or Without Concomitant Thrombosis
Status: Enrolling
Updated: 8/18/2014
The Elite Laser Vein Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Raj K. Maturi, MD
mi
from
Indianapolis, IN
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Raj K. Maturi, MD
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Beetham Eye Institute
mi
from
Boston, MA
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Beetham Eye Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Palmetto Retina Center
mi
from
West Columbia, SC
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Palmetto Retina Center
mi
from
West Columbia, SC
Click here to add this to my saved trials
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated:  8/19/2014
Valley Retina Institute, P.A.
mi
from
McAllen, TX
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Status: Enrolling
Updated: 8/19/2014
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Birmingham, AL
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
La Jolla, CA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
San Francisco, CA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Atlanta, GA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Macon, GA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Baltimore, MD
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Petoskey, MI
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Petoskey, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Newark, NJ
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Hickory, NC
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Fairfield, OH
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Fairfield, OH
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated:  8/26/2014
ValleyCare Health System-Pleasanton
mi
from
Pleasanton, CA
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated: 8/26/2014
ValleyCare Health System-Pleasanton
mi
from
Pleasanton, CA
Click here to add this to my saved trials
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated:  8/26/2014
UMD School of Medicine
mi
from
Baltimore, MD
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated: 8/26/2014
UMD School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated:  8/26/2014
Geisinger Heart Institute
mi
from
Danville, PA
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated: 8/26/2014
Geisinger Heart Institute
mi
from
Danville, PA
Click here to add this to my saved trials
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated:  8/26/2014
Lankenau MOB East
mi
from
Wynnewood, PA
Video-Assisted Left Atrial Appendage Exclusion Trial
A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery ("VATS")
Status: Enrolling
Updated: 8/26/2014
Lankenau MOB East
mi
from
Wynnewood, PA
Click here to add this to my saved trials